Evolution of epilepsy prevalence and incidence in a Tanzanian area endemic for onchocerciasis and the potential impact of community-directed treatment with ivermectin: a cross-sectional study and comparison over 28 years

dc.contributor.authorGreter, H.
dc.contributor.authorMmbando, B.
dc.contributor.authorMakunde, W.
dc.contributor.authorMnacho, M.
dc.contributor.authorMatuja, W.
dc.contributor.authorKakorozya, A.
dc.contributor.authorSuykerbuyk, P.
dc.contributor.authorColebunders, R.
dc.date.accessioned2018-09-25T11:51:50Z
dc.date.available2018-09-25T11:51:50Z
dc.date.issued2018
dc.description.abstractIntroduction Worldwide, there are an estimated 50 million people affected by epilepsy. Its aetiology is manifold, and parasitic infections play an important role, specifically onchocerciasis. In onchocerciasis endemic areas, a distinctive form of epilepsy has been described as nodding syndrome, affecting children and causing nodding seizures, mental retardation and debilitating physical development. Onchocerciasis control programmes using community-directed treatment with ivermectin (CDTI) are implemented in endemic countries. This study is designed to contribute to a better understanding of the linkage between the onset of epilepsy, onchocerciasis and CDTI. Comparing the epidemiological data on epilepsy and onchocerciasis from pre-CDTI and 20 years after its introduction will allow identifying a potential impact of ivermectin on the onset of epilepsy. Methods and analysis The study will be conducted in the Mahenge highlands in Tanzania. Study site selection is based on an in-depth study on epilepsy in that area dating from 1989. CDTI was introduced in 1997. By a door-to-door approach, the population will be screened for epilepsy using a validated questionnaire. Suspected cases will be invited for a neurological examination for case verification. Onchocerciasis prevalence will be assessed by a rapid epidemiological assessment. As an indicator for ongoing transmission, children younger than 10 years of age will be tested for Ov16 antibodies. Ivermectin use will be assessed at household level. Epilepsy data will be analysed in comparison with the 1989 data to reveal pre-CDTI and post-CDTI prevalence and incidence. Ethics and dissemination The protocol has received ethical approval from the ethics committees of the University of Antwerp, Belgium, and of the National Institut of Medical Research, Dar es Salaam, Tanzania. The findings will be published in peer-reviewed journals, and presented to the health authorities in Tanzania, at national, regional and village level.en_US
dc.identifier.citationGreter H, Mmbando B, Makunde W, et al. Evolution of epilepsy prevalence and incidence in a Tanzanian area endemic for onchocerciasis and the potential impact of community-directed treatment with ivermectin: a crosssectional study and comparison over 28 years. BMJ Open 2018;8:e017188. doi:10.1136/ bmjopen-2017-017188en_US
dc.identifier.uridoi:10.1136/bmjopen-2017-017188
dc.identifier.urihttp://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/2204
dc.language.isoenen_US
dc.publisherBMJen_US
dc.relation.ispartofseriesBMJ open;8:e017188
dc.subjectEpilepsyen_US
dc.subjectPrevalanceen_US
dc.subjectOnchocerciasisen_US
dc.subjectIvermectinen_US
dc.subjectTanzaniaen_US
dc.subjectEpilepsy epidemiologyen_US
dc.titleEvolution of epilepsy prevalence and incidence in a Tanzanian area endemic for onchocerciasis and the potential impact of community-directed treatment with ivermectin: a cross-sectional study and comparison over 28 yearsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Greater, H. 2018.pdf
Size:
833.68 KB
Format:
Adobe Portable Document Format
Description:
Protocol

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description: